The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | The management of patients with lenalidomide-refractory multiple myeloma in the UK
In this video, Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, briefly comments on the management of patients with lenalidomide-refractory multiple myeloma (MM) in the United Kingdom, highlighting that this is a challenging patient population to treat. This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So we know that many patients now, if they complete frontline therapy, will be Len-refractory. So if you’re on Len maintenance following a stem cell transplant and you relapse, clearly you’re Len-refractory. If you relapse on lenalidomide when you’re on the MAIA regimen of Daratumumab-Revlimid-Dex, then you’re going to be Len-refractory. And we know that patients who are Len-refractory are a difficult group of patients to treat...
So we know that many patients now, if they complete frontline therapy, will be Len-refractory. So if you’re on Len maintenance following a stem cell transplant and you relapse, clearly you’re Len-refractory. If you relapse on lenalidomide when you’re on the MAIA regimen of Daratumumab-Revlimid-Dex, then you’re going to be Len-refractory. And we know that patients who are Len-refractory are a difficult group of patients to treat. So I think you obviously have to think about your next line of therapy with that in mind. You need different lines of therapy. You need a proteasome inhibitor. You might need to reintroduce anti-CD38 antibodies. You might use selinexor. And you may think about future IMiD use such as pomalidomide, but obviously you can’t use that until the fourth line setting, which is difficult.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Johnson & Johnson, Amgen, Sanofi, Bristol Myers Squibb, Takeda, Pfizer, Menarini: Honoraria for advisory boards/speaking; Onyx, Bristol Myers Squibb, Takeda: Research Funding.
